세계의 면역종양 어세이 시장 : 적응증별, 제품별, 기술별, 용도별 예측(2025-2030년)

The Immuno Oncology Assays Market was valued at USD 6.26 billion in 2023, expected to reach USD 7.21 billion in 2024, and is projected to grow at a CAGR of 15.26%, to USD 16.93 billion by 2030.

Immuno-oncology assays are critical diagnostic tools used to assess the immune response to cancer therapies, thus playing a crucial role in personalized cancer treatment. They are necessary for monitoring and evaluating patient responses to immunotherapies, ensuring more effective, targeted cancer treatments with improved outcomes. The application of these assays includes identifying biomarkers, determining immune cell infiltration in tumors, and optimizing novel therapeutic approaches. Predominant end-users include research laboratories, pharmaceutical companies, and clinical diagnostic centers. The growing prevalence of cancer, increasing adoption of immunotherapies, and advancements in precision medicine drive market growth. Furthermore, government funding in cancer research combined with technological innovations in biomarker discovery bolster the market. The latest potential opportunities lie in expanding applications in combination therapies and emerging biomarkers for various cancer types. To seize these opportunities, investment in advanced technologies like multiplexed assays that can concurrently analyze multiple biomarkers is recommended. However, market expansion faces several limitations, including high costs, which can restrain adoption rates, alongside regulatory hurdles that slow the introduction of new assays. Additionally, the complexity of immune responses and the biological variability between patients pose significant challenges. Key areas for innovation and research involve developing assays that offer higher sensitivity and specificity while being cost-effective. Integration with digital technologies, such as AI for data analysis and improved automation in labs, represents a promising frontier. The market is competitive yet fragmented, characterized by the presence of numerous established players and growing interest from new entrants, driving innovation and enhancing product offerings. Continuous R&D and strategic partnerships are essential to foster knowledge exchange and leverage cutting-edge discoveries, shaping the future landscape of immuno-oncology diagnostics.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Immuno Oncology Assays Market

The Immuno Oncology Assays Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing incidences of cancer and adoption of targeted therapy over other treatment options
  • Development of bioinformatic tools enhancing the drug development process
  • Rise in healthcare expenditure and healthcare insurance
• Market Restraints
  • Unfavorable regulatory and reimbursement scenario
• Market Opportunities
  • Technological advancement and R&D for the treatment of cancer
  • Emergence of companion diagnostics
• Market Challenges
  • Lack of healthcare professions for device operation

Porter's Five Forces: A Strategic Tool for Navigating the Immuno Oncology Assays Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Immuno Oncology Assays Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Immuno Oncology Assays Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Immuno Oncology Assays Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Immuno Oncology Assays Market

A detailed market share analysis in the Immuno Oncology Assays Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Immuno Oncology Assays Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Immuno Oncology Assays Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Immuno Oncology Assays Market

A strategic analysis of the Immuno Oncology Assays Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Immuno Oncology Assays Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., BioAgilytix Labs, LLC, Charles River Laboratories International, Inc., ElsaLys Biotech S.A., Eurofins DiscoverX Products, LLC, HTG Molecular Diagnostics, Inc., Illumina, Inc., Merck KGaA, NanoString Technologies, Inc., NeoGenomics Laboratories, Inc., PerkinElmer, Inc., QIAGEN GmbH, Sartorius AG, Thermo Fisher Scientific, Inc., and Twist Bioscience Corporation.

Market Segmentation & Coverage

This research report categorizes the Immuno Oncology Assays Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Indication, market is studied across Bladder Cancer, Colorectal Cancer, Lung Cancer, and Melanoma.
• Based on Product, market is studied across Consumables and Software.
• Based on Technology, market is studied across Flow Cytometry, Immunoassay, Next-Generation Sequencing, and Polymerase Chain Reaction.
• Based on Application, market is studied across Clinical Diagnostics and Research.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing incidences of cancer and adoption of targeted therapy over other treatment options
    • 5.1.1.2. Development of bioinformatic tools enhancing the drug development process
    • 5.1.1.3. Rise in healthcare expenditure and healthcare insurance
  • 5.1.2. Restraints
    • 5.1.2.1. Unfavorable regulatory and reimbursement scenario
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancement and R&D for the treatment of cancer
    • 5.1.3.2. Emergence of companion diagnostics
  • 5.1.4. Challenges
    • 5.1.4.1. Lack of healthcare professions for device operation
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Immuno Oncology Assays Market, by Indication

• 6.1. Introduction
• 6.2. Bladder Cancer
• 6.3. Colorectal Cancer
• 6.4. Lung Cancer
• 6.5. Melanoma

7. Immuno Oncology Assays Market, by Product

• 7.1. Introduction
• 7.2. Consumables
• 7.3. Software

8. Immuno Oncology Assays Market, by Technology

• 8.1. Introduction
• 8.2. Flow Cytometry
• 8.3. Immunoassay
• 8.4. Next-Generation Sequencing
• 8.5. Polymerase Chain Reaction

9. Immuno Oncology Assays Market, by Application

• 9.1. Introduction
• 9.2. Clinical Diagnostics
• 9.3. Research

10. Americas Immuno Oncology Assays Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Immuno Oncology Assays Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Immuno Oncology Assays Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Agilent Technologies, Inc.
• 2. Bio-Rad Laboratories, Inc.
• 3. BioAgilytix Labs, LLC
• 4. Charles River Laboratories International, Inc.
• 5. ElsaLys Biotech S.A.
• 6. Eurofins DiscoverX Products, LLC
• 7. HTG Molecular Diagnostics, Inc.
• 8. Illumina, Inc.
• 9. Merck KGaA
• 10. NanoString Technologies, Inc.
• 11. NeoGenomics Laboratories, Inc.
• 12. PerkinElmer, Inc.
• 13. QIAGEN GmbH
• 14. Sartorius AG
• 15. Thermo Fisher Scientific, Inc.
• 16. Twist Bioscience Corporation